Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.69 USD
Change Today +0.03 / 1.81%
Volume 175.7K
MEIP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

mei pharma inc (MEIP) Snapshot

Open
$1.70
Previous Close
$1.66
Day High
$1.72
Day Low
$1.66
52 Week High
10/13/14 - $8.33
52 Week Low
08/3/15 - $1.47
Market Cap
57.7M
Average Volume 10 Days
538.8K
EPS TTM
$-1.48
Shares Outstanding
34.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEI PHARMA INC (MEIP)

Related News

No related news articles were found.

mei pharma inc (MEIP) Related Businessweek News

No Related Businessweek News Found

mei pharma inc (MEIP) Details

MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

mei pharma inc (MEIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $482.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Chief Medical Officer
Total Annual Compensation: $153.6K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $70.6K
Compensation as of Fiscal Year 2014.

mei pharma inc (MEIP) Key Developments

MEI Pharma, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:40 PM

MEI Pharma, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:40 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Daniel P. Gold, Chief Executive Officer, President and Director.

MEI Pharma, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM

MEI Pharma, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Daniel P. Gold, Chief Executive Officer, President and Director.

MEI Pharma, Inc. Reports Updated Results from Phase II Study of Pracinostat and Azacitidine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

MEI Pharma, Inc. announced updated results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. To date, 27 of 50 patients (54%) have achieved the primary endpoint of complete response (CR) plus complete response with incomplete blood count recovery (CRi) plus morphologic leukemia-free state (MLFS), including 16 patients (32%) who achieved a CR. The response rate from this study compares favorably with previous studies of azacitidine alone in this population1. Most responses occur within the first two cycles and continue to improve with ongoing therapy. Median overall survival has not yet been reached in the study, with 32 patients (64%) still being followed (range, 6-15 months). Survival of patients with intermediate-risk cytogenetic abnormalities appears greater than that for patients with high-risk cytogenetics, though neither subset of patients has reached median survival. The 60-day mortality rate, often used as a benchmark in AML clinical studies, was 10% (5 of 50). Pracinostat in combination with azacitidine was well tolerated in this population of elderly AML patients. The most common treatment-emergent adverse events (AEs) included febrile neutropenia, thrombocytopenia, nausea and fatigue. AEs resulting in dose reductions were frequently due to disease under study. Nearly half of the patients (22 of 50) to date have received study drug beyond six months, reflecting long-term tolerability.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEIP:US $1.69 USD +0.03

MEIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MEIP.
View Industry Companies
 

Industry Analysis

MEIP

Industry Average

Valuation MEIP Industry Range
No financial data is available for MEIP.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEI PHARMA INC, please visit www.meipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.